Teva NDA for first-in-class pediatric Tourette syndrome therapy

 Teva submits FDA New Drug Application for ecopipam, first-in-class pediatric Tourette syndrome therapy from Emalex acquisition

https://finviz.com/stock?t=TEVA&p=d